ABT Trading Analysis - 10/21/2026 01:59 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• Abbott (ABT) recently received FDA clearance for a next-gen continuous glucose monitoring device, supporting its diabetes-care growth segment.
• The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of October 15, 2026, reflected in the fundamentals data.
• Broader medical-device supply-chain constraints have eased, but hospital budgeting remains cautious into year-end.
• ABT's defensive profile (low beta ~0.34) has attracted income-focused investors amid macro uncertainty.
• No major earnings catalyst until next fiscal reporting period; recent price softness may reflect sector rotation rather than fundamental deterioration.

Context: Steady dividend and product clearance news contrast with the embedded data showing a pullback from October highs and balanced options sentiment, suggesting no immediate directional catalyst in the flow.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for ABT:

• Trailing P/E is 33.20 and trailing EPS is $3.14; forward P/E, PEG, and profit-margin fields are null, so valuation appears elevated versus typical staples peers but in line with healthcare innovators.
• Dividend yield is 2.42% with rate $2.52 and ex-dividend 2026-10-15; supports income appeal.
• Market cap is $170,918,580,825 with shares out 1,730,383,000 and institutional ownership 58.71%.
• Beta is 0.34 (low volatility); 52-week range $81.97 to $132.03, price near lower-mid.
• Revenue growth, gross/operating/net margins, ROE, debt/equity, and free cash flow are null — not available in data.
• Analyst target mean and recommendation key are null; no consensus projection embedded.
• Fundamentals show stable yield and low beta, diverging from technical weakness (price below 50-day SMA of $105.68) and recent down-momentum.

Current Market Position

From embedded data: Daily close on 2026-10-20 was $102.76 after opening $105.53 and trading as low as $100.75 on volume 10,161,639 (above 20-day avg 5,519,956). Minute bars show 2026-10-20 09:30 close $105.49 sliding to 2026-10-21 13:30 close $98.67, indicating sustained intraday weakness. Current price per indicators is $102.76 (as of 2026-10-20), but minute last print $98.67 suggests further drift.

Intraday momentum from minute bars is bearish: lower highs and lows from $105.49 to $98.67 over the session window.

Technical Analysis

SMA alignment: Price $102.76 is below SMA 5 ($103.82) and SMA 50 ($105.68) but above SMA 20 ($100.98) — no golden/death cross active, but bearish tilt vs 50-day. RSI 61.94 shows moderate momentum, not overbought. MACD -0.11 below signal -0.09 with hist -0.02 confirms mild bearish momentum. Bollinger: middle $100.98, upper $105.75, lower $96.22; price near middle-upper. 30-day range high $106.86, low $95.06; price sits ~38% up the range. ATR 2.53 implies daily swing risk.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-21) shows sentiment Balanced. Call dollar vol $502,455 (55.8%), put $398,210 (44.2%), total $900,665. Call contracts 1,765 vs put 1,492. Pure directional conviction is neutral with slight call tilt.

Conviction: Balanced read suggests no strong near-term directional expectation; minor call premium may reflect defensive income holders. Divergence: Technicals lean bearish (price < 50 SMA, MACD neg) while flow is balanced — not confirming downside urgency.

Key Price Levels (Observational Only)